4340 Duncan Avenue St. Louis, MO 63110 314-615-6355 info@biogenerator.org

BioGenerator Company Confluence Life Sciences Acquired By Aclaris Therapeutics

Aug 08, 2017

ST. LOUIS –BioGenerator’s largest investment in any single company is paying off for St. Louis. Confluence Life Sciences, Inc. has been acquired by Aclaris Therapeutics, Inc. (NASDAQ: ACRS) for the St. Louis company’s world-class research team, intellectual property, and drug discovery assets.

The terms of the deal provide for Confluence to receive $20 million upfront, equally split between cash and stock and subject to customary adjustments. Confluence shareholders also are eligible to receive up to $80 million in contingent payments upon the achievement of certain development, regulatory, and commercial milestones, as well as potential royalty payments on drug product sales.

BioGenerator’s closing proceeds from its $1.4 million investment in Confluence will be reinvested into new St. Louis companies and used to improve the St. Louis innovation ecosystem. BioGenerator is the investment arm of BioSTL.

Read the Full Press Release Here

See the Press Conference